Work

An Evaluation of Ibrutinib and Ixazomib in Patients With Relapsed/Refractory Mantle Cell Lymphoma: PrE0404

Year: 2026

Type: article

Study design: Clinical Trial

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/j.clml.2026.04.025

Authors: Jonathon B. Cohen, Craig A. Portell, Mehdi Hamadani, Opeyemi Jegede, Catherine Diefenbach, Christopher Fletcher, Matthew Matasar, Daniel Landsburg, Suparna Mantha, Brad Kahl

Institutions: Emory University, Winship Cancer Institute, University of Virginia Medical Center, University of Virginia Cancer Center, Medical College of Wisconsin, Dana-Farber Cancer Institute, NYU Langone Health, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, University of Wisconsin–Madison, Rutgers Cancer Institute, University of Pennsylvania, Carle Foundation Hospital, Washington University in St. Louis

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7160106405

FWCI: 4.551

Cites: 22

Cited by: 1

Related to: 10